Heavy Periods, Iron Levels, and a Cancer Drug's Surprise Role
This episode covers three research stories: a Chinese retrospective study on endometrial ablation for heavy periods that won't respond to other treatment, new lab research into how the breast cancer drug fulvestrant interacts with estrogen receptors, and a large U.S. dataset connecting iron levels to the pace of biological aging. Key Takeaways: • Endometrial ablation reduced or stopped heavy periods in the majority of patients in this study, but younger age and a larger uterine cavity were associated with higher recurrence rates — worth knowing before deciding. • The fulvestrant study is…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.